Pathy's Principles and Practice of Geriatric Medicine. Группа авторов

Pathy's Principles and Practice of Geriatric Medicine - Группа авторов


Скачать книгу
for enriched grain product to require addition of folic acid. Fed Regist. 1996; 61:8781.

      44 44. Sanford AM, Flaherty JH. Do nutrients play a role in delirium? Curr Opin Clin Nutr Metab Care. 2014; 17(1):45‐50.

      45 45. Khan KM, Jialal I. Folic Acid (Folate) Deficiency. StatPearls Publishing; 2020.

      46 46. Scott J, Weir D. Folate/vitamin B12 inter‐relationshiprs. Essays Biochem. 1994; 28:63‐72.

      47 47. Sobczynska‐Malefora A, Harrington D. Laboratory assessment of folate (vitamin B9 status). J Clin Path. 2018; 71(11):949‐56.

      48 48. Joosten E, Lioen P. Iron deficiency anemia and anemia of chronic disease in geriatric hospitalized patients: how frequent are comorbidities as an additional explanation for the anemia? Geriatr Gerontol Int. 2014; 15(8):931‐5.

      49 49. Careaga M, Moize V, Flores L, et al. Inflammation and iron status in bariatric surgery candidates. Surg Obes Relat Dis. 2015; 11(4):906‐11.

      50 50. Pietrangelo A. Physiology of iron transport and the hemochromatosis gene. Am J Physiol Gastrointest Liver Physiol. 2002; 282:G403‐414.

      51 51. Nemeth E, Rivera S, Gabayan V, et al. IL‐6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113:1271‐6.

      52 52. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res. 1998; 18:555‐9.

      53 53. Moldawer LL, Marano MA, Wei H, et al. Cachectin/tumor necrosis factor‐alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J. 1989; 3:1637‐43.

      54 54. Maciejewski JP, Selleri C, Sato T, et al. Nitric oxide suppression of human hematopoiesis in vitro: contribution to inhibitory action of interferon‐gamma and tumor necrosis factor‐alpha. J Clin Invest. 1995; 96:1085‐92.

      55 55. Skikne BS, Punnonen K, Caldron PH, et al. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J Hematol. 2011; 86(11):923‐27.

      56 56. Weiss G. Iron and immunity: a double‐edged sword. Eur J Clin Invest. 2002; 32:Supple 1 70‐80.

      57 57. Kletzmayr J, Sunder‐Plassmann G, Horl WH. High dose intravenous iron: a note of caustion. Nephrol Dial transplant. 2002; 17:962‐5.

      58 58. Weiss G, Goodnough L. Anemia of chronic disease. N Engl J Med. 2005; 352:1011‐23.

      59 59. Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem. 203; 49:1573‐8.

      60 60. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence‐based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002; 20:4083‐4107.

      61 61. National Kidney Foundation. KEEP 2004 annual data report. Am J Kidney Dis. 2005; 45(suppl 2):S1‐80.

      62 62. McClellan W, Resnick B, Lei L, et al. Prevalence and severity of chronic kidney disease and anemia in the nursing home population. J Am Med Dir Assoc. 2010; 11:33‐41.

      63 63. Ma JZ, Ebben J, Xia H, et al. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999; 10:610‐9.

      64 64. Moreno F, Sanz‐Guajardo D, Lopez‐Gomez, JM, et al. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients: Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol. 2000: 11:335‐42.

      65 65. Besarab A, Ayyoub F. Anemia in renal disease: Diseases of the Kidney and Urinary Tract, 8th ed. Lippincott Williams and Wilkins; 2007:2406–2430.

      66 66. Hunsicker L, Levey A. Progression of chronic renal disease: mechanisms, risk factors, and testing of interventions. The Principles and Practice of Nephrology. Mosby; 1995:622‐31.

      67 67. Anapalahan M, Savvas S, Lo K, et al. Chronic idiopathic normocytic anaemia in older people: the risk factors and the role of age‐associated renal impairment. Aging Clin Exp Res. 2017; 29:147‐55.

      68 68. Nielson O, Thayson J. Erythropoietin deficiency in acute renal failure. Lancet. 1989; 1:634‐5.

      69 69. Cotes PM, Tam RC, Reed P, et al. An immunological cross‐reactant of erythropoietin in serum which may invalidate EPO radioimmunoassay. BR J Haematol. 1989; 73:265‐68.

      70 70. NKF‐K/DOQI Clinical Practice Guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis. 2001: 37:Suppl 1:S182–S238.

      71 71. Phrommintikul A, Haas SJ, Elsik M, et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta‐analysis. Lancet. 2007; 369:381‐88.

      72 72. KDOQI, National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006; 47(5 Supple 3):S11‐145.

      73 73. Bennett CL, Becker PS, Kraut EH et al. Intersecting guidelines: administering erythropoiesis‐stimulating agents to chronic kidney disease patients with cancer. Semin Dial. 2009; 22:1‐4.

       Kingsley K. Hampton

      Royal Hallamshire Hospital, Sheffield, UK


Скачать книгу